In addition, his institution has received grant support from Allergan, Boehringer Ingelheim, Bristol Myers Squibb ... lab service agreements from Enanta, Gilead, ICON, Intercept, NuSirt, Shire, ...

Christian Boehringer to hand over as Chairman of the Shareholders’ Committee to Hubertus von Baumbach Shashank Deshpande, Member of the Board of ...

Partnership bolsters Boehringer’s autoimmune and inflammatory disease pipeline portfolio aiming to tackle areas of high unmet patient need. The ...

At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address ...

IT can’t sit back - the company’s 2,000 technology professionals must drive the identification of digital solutions to ...

Boehringer Ingelheim and Cue Biopharma Inc. have joined forces to develop and commercialize Cue Biopharma’s CUE-501 product candidate.

Boehringer Ingelheim and Cue Biopharma have entered a strategic research partnership and licence agreement to develop and commercialise the latter’s CUE-501 product candidate for autoimmune ...

The agreement focuses on further research and development of a novel, first-in-class bispecific compound for T cell mediated targeted depletion of specific B cells to address autoimmune and ...

“By providing tools, trust and opportunities for growth, Boehringer Ingelheim ensures employees like myself develop alongside the company’s mission to advance animal health. “For someone overseeing ...

Hubertus von Baumbach joined Boehringer Ingelheim in 2001. He held various leadership positions in Finance & Controlling, until he was appointed to the Board of Managing Directors in 2009 ...

Germany's largest pharmaceutical company Boehringer Ingelheim on Wednesday reported a currency-adjusted 6.1% gain in 2024 revenues, buoyed by diabetes drug Jardiance and lung drug Ofev.